CCCC — C4 Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $461.00m
- $207.32m
- $20.76m
- 16
- 12
- 87
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 21.4 | 33.2 | 45.8 | 31.1 | 20.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 56.8 | 93.6 | 128 | 161 | 160 |
Operating Profit | -35.5 | -60.4 | -82.1 | -130 | -140 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.3 | -67 | -83.9 | -128 | -131 |
Provision for Income Taxes | |||||
Net Income After Taxes | -34.1 | -66.3 | -83.9 | -128 | -132 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.1 | -66.3 | -83.9 | -128 | -132 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -42.6 | -66.3 | -83.9 | -128 | -132 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.02 | -1.54 | -1.82 | -2.62 | -2.66 |
Dividends per Share |